another example .. be patient ..., page-4

Some people might not understand the way this company (MLA) works. They both manufacture and distribute certain products.

In the case of Medivet, they are world leaders in this technology - providing stem cell harvest kits to vets. Pretty amazing (but understanding) how far ahead vet science is to human science - vets are already able to regenerate and deliver cells to animals in order to repair limbs and organs. With the Medivet solution, this process is no longer required to be done by specialist labs - it can be done at each vet practice that has these Adipose Stem Cell kits.

So to understand what this is all about:

- MLA have world rights to manufacturer this kit on behalf of Medivet

So as this industry booms, so does MLA - pretty simple really.

Now, the other advantage of manufacturing for the leading supplier of these kits?

- MLA has negotiated for Medivet to distribute its transfusion and infusion kits - to put it simply/crudely, the stuff that is used in most operative veterinary procedures.

What they have going with Medivet is a fantastic symbiotic relationship in a exponentially booming industry - each is taking advantage of what the other has in oredr to generate more revenue for themselves.

The other important point here is that MLA are not involved in the expensive R&D of the Medivet kit - the hard work has already been done in terms of R&D and approvals. MLA is tacking on their value after all the hard work has been done and are able to reap the rewards of the all important sales.

The market is caning Biotech development houses at the moment - not valuing the fundamentals of what they are doing and instead, only rewarding these companies once/if the drugs/developments are commercialised.

MLA is in a space where they are at the commercialisation side of their industry - what more could we ask for...screaming buy!